Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

  1. Dimopoulos, M.A.
  2. Terpos, E.
  3. Boccadoro, M.
  4. Delimpasi, S.
  5. Beksac, M.
  6. Katodritou, E.
  7. Moreau, P.
  8. Baldini, L.
  9. Symeonidis, A.
  10. Bila, J.
  11. Oriol, A.
  12. Mateos, M.-V.
  13. Einsele, H.
  14. Orfanidis, I.
  15. Kampfenkel, T.
  16. Liu, W.
  17. Wang, J.
  18. Kosh, M.
  19. Tran, N.
  20. Carson, R.
  21. Sonneveld, P.
Revue:
The Lancet Haematology

ISSN: 2352-3026

Année de publication: 2023

Volumen: 10

Número: 10

Pages: e813-e824

Type: Article

DOI: 10.1016/S2352-3026(23)00218-1 GOOGLE SCHOLAR